Project Grant R01HL175766
Award Date
1/1/25
Completion Date
11/30/28
Dollars Obligated
$698K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,259 to the University of California, Los Angeles (UCLA) to support research on the relationship between membrane cholesterol, vascular inflammation, and cardiovascular disease. The key objectives are to: 1) identify novel cholesterol-responsive proteins in the vasculature; 2) define molecular mechanisms by which membrane cholesterol regulates inflammatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $236,833 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel intracellular targeting nanobody that blocks Connexin 43 (Cx43)-mediated pathological proliferation of smooth muscle cells (SMCs). The project aims to design and test these small antibody fragments called nanobodies, which can enter cells, to disrupt the Cx43-Cyclin E...
The federal Project Grant award R01HL176666, totaling $767,077.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award aims to validate and extend a platform technology for the delivery of protein-based drugs, with a specific focus on thrombolytic enzymes and vitamin B12. The research seeks to develop a biocompatible drug delivery system that leverages the circulatory system as a natural drug depot and utilizes...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $601,677 to the University of Massachusetts for a research project titled "Multi-Scale Characterization of Antigen-Polymerized Immune Complexes Underlying Thrombotic Pathologies Triggered by Adenoviral-Vectored Vaccines". The project aims to study the mechanism behind a rare but dangerous side effect called vaccine-induced immune thrombotic...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This Project Grant award of $540,856 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the gene regulatory networks that control endocardial-specific gene expression. The key objectives are to: 1) Identify transcriptional regulators of endocardial-restricted gene expression, 2) Determine how valve-restricted gene expression is achieved, and 3) Define the regulation and function of the SLC16A2 gene during heart injury...
This Project Grant award, valued at $402,911.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a method for generating a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be tested for their ability to promote tissue repair in mouse and porcine models of cardiac...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $167,400 to Brigham & Women's Hospital to investigate how the immune mediator CD70 regulates endothelial function and metabolism, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year award, beginning March 1, 2025, supports research to elucidate: 1) CD70 regulation of endothelial nitric oxide synthase;...